Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.18 USD
+0.02 (1.00%)
Updated May 3, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth D Momentum A VGM
Brokerage Reports
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 1 - 20 ( 121 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Good End to the Year of The Core; Improvements Ahead in ''24
Provider: Wedbush Securities Inc.
Analyst: PASCARELLI G
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
4Q24 Solid, Margin CF Improvement on Efficiency Gains to Continue
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Strong Q423 Shows Improved Strategic Focus and Rightsized Cost Structure. Catalysts Approaching. Upgrading to BUY.
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: February Performance and Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: U.S. Cannabis 4Q23 Earnings Week I
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Capital Remains Tight but Will Flow with Federal Reform Changes
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Percolating Cannabis Technicals, Trading Volume, Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Pressure on DEA to Reschedule After HHS Findings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: State Led Growth Story to Continue in 2024
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Yearly ReHash: Biggest Developments in Cannabis in 2023
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: New York Set to Expand Adult-use in 2024
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Green Wednesday - Cannabis Industry''s Black Friday
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
3Q23 Beat, Lean Core Ops Improves Margins and Cash Flow Without Growth
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Strong Q323 Print. Still Relatively Few Immediate Growth Drivers
Provider: Echelon Welath Partners
Analyst: SEMPLE A